Evidence map›Paper›PMID 42382136›Full record

ArticleEClinicalMedicine2026

WHO Global Antimicrobial Resistance Surveillance System (GLASS) for monitoring bloodstream infections due to

Daniel Marcano Zamora, Sergey Eremin, Pilar Ramon-Pardo, Agustina Forastiero, Marcelo Galas, Daniel A da Matta, Diego Nobrega, Zlatina Dobreva, Methee Chayakulkeeree, Jong Hee Shin and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Daniel Marcano ZamoraAntimicrobial Resistance Department, World Health Organization, Geneva, Switzerland.
Sergey EreminAntimicrobial Resistance Department, World Health Organization, Geneva, Switzerland.
Pilar Ramon-PardoAMR Special Program. Communicable Diseases Prevention, Control and Elimination Department, Pan American Health Organization/WHO, Washington, D.C., USA.
Agustina ForastieroAMR Special Program. Communicable Diseases Prevention, Control and Elimination Department, Pan American Health Organization/WHO, Washington, D.C., USA.
Marcelo GalasAMR Special Program. Communicable Diseases Prevention, Control and Elimination Department, Pan American Health Organization/WHO, Washington, D.C., USA.
Daniel A da MattaRodolphe Mérieux Laboratory, Rio Branco, Brazil.
Diego NobregaFaculty of Veterinary Medicine, University of Calgary, Calgary, Canada.
Zlatina DobrevaNuffield Department of Primary Health Sciences, University of Oxford, Oxford, United Kingdom.
Methee ChayakulkeereeDepartment of Medicine, Mahidol University, Bangkok, Thailand.
Jong Hee ShinDepartment of Laboratory Medicine, Green Cross Laboratories, Gwangju, Republic of Korea.
Susana ZuritaNational Reference Laboratory for Mycology, National Center for Public Health, National Institute of Health, Lima, Peru.
Arunaloke ChakrabartiDoodhadhari Burfani Hospital and Research Institute, Haridwar, India.
Anuradha ChowdharyDepartment of Medical Microbiology, Vallabhbhai Patel Chest Institute, University of Delhi, India.
Ana Alastruey-IzquierdoMycology Reference Laboratory, Instituto de Salud Carlos III, Madrid, Spain.
Susana CordobaInstituto Nacional de Enfermedades Infecciosas Dr. Carlos G Malbrán, Buenos Aires, Argentina.
Jana WelnaAntoni Jurasz University Hospital No. 1, Bydgoszcz, Poland.
Nelesh P GovenderWits Mycology Division, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Alexandre AlanioHospital Saint-Louis, Paris, France.
Arnaldo Lopes ColomboAntimicrobial Resistance Institute of São Paulo, Universidade Federal de São Paulo, São Paulo, Brazil.
Ivana MarekovićUniversity Hospital Centre Zagreb, Zagreb, Croatia.
Ingibjorg HilmarsdottirLandspitali - National University Hospital of Iceland, Reykjavík, Iceland.
Silvia BertagnolioAntimicrobial Resistance Department, World Health Organization, Geneva, Switzerland.
Carmem L Pessoa-SilvaFederal University of Rio de Janeiro, Rio de Janeiro, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Antimicrobial resistance (AMR) in Methods: The GLASS-Fungi pilot was a multicentre observational demonstration study where twenty-four laboratories were invited to collect and share Findings: Fourteen laboratories from 13 countries contributed data from 3447 patients with candidemia. Overall, Interpretation: The study was a global, multi-centre initiative to systematically collect and report surveillance data on Funding: This work was supported by the United States Centers for Disease Control and Prevention.

Indexed as

AMRCandidemiaGLASS

Identifiers

PMID42382136
PMCPMC13316650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.